Tetraphase's Broad Spectrum Antibiotic Xerava Priced To Move
Company presents game plan for targeting 1,900 high-prescribing hospitals in US in a launch kicking off in the second half of October.
You may also be interested in...
Deal Snapshot: Unable to make a go of selling novel antibiotic Xerava, Tetraphase’s product and commercial team will be absorbed into AcelRx in $14.4m deal.
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Promising drugs from Tetraphase, ContraFect, Spero and Entasis get a platform at the Infectious Diseases Society of America’s IDWeek.